CARDIFF ONCOLOGY
Cardiff Oncology is a clinical-stage oncology therapeutics company developing drugs that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers. It has a broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. The company offers its PCM technology at its CLIA/CAP-accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics. Cardiff Oncology (formerly known as Trovagene) was founded in 1999 and is headquartered in San Diego, California.
CARDIFF ONCOLOGY
Industry:
Biotechnology Health Care Health Diagnostics Medical
Founded:
1999-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.cardiffoncology.com
Total Employee:
11+
Status:
Active
Contact:
+1 858-952-7570
Email Addresses:
[email protected]
Total Funding:
80.46 M USD
Technology used in webpage:
SPF Google Font API Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail IPv6 Google Maps GoDaddy DNS Google PHP 7
Similar Organizations
ABT Molecular Imaging
ABT Molecular Imaging develops a production platform to generate unit doses of molecular imaging drugs for PET scanning at the point of use.
ADMA Biologics
ADMA Biologics develops plasma-based biologics for the treatment and prevention of certain infectious diseases.
Apollo Hospitals Enterprise
Apollo Hospitals is a premium multi-specialty hospital of India and is one of the largest integrated healthcare groups.
Atonarp
Atonarp combines electronics and data processing algorithms for chemical composition analysis.
Tarveda Therapeutics
Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
CellPhire
Cellphire has developed a proprietary method for the stabilization of blood in the dry state
CVRx
CVRx is a medical device company developing implantable technology for the treatment of high blood pressure.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Vero Biotech
Vero Biotech is a biopharmaceutical company that commercializes inhaled nitric oxide delivery systems for healthcare providers.
GluMetrics
GluMetrics, a medical company based in Irvine, California, develops tools that enable clinicians to implement a care paradigm for patients.
Kipu Health
SaaS platform for behavioral health and addiction treatment centers providing EHR, patient engagement and RCM solutions.
NanoString Technologies
NanoString Technologies provides a life science tools platform for a variety of basic research, translational medicine and IVD applications.
NeoGenomics
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
Knopp Biosciences
Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.
Omega Diagnostics
Omega Diagnostics provides IVD products for use in hospitals, blood banks, clinics, and laboratories.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Thyrocare Technologies
Thyrocare Technologies Limited is India's first fully automated diagnostic laboratory.
Current Employees Featured
Founder
Stock Details
Investors List
Pfizer Breakthrough Growth Initiative
Pfizer Breakthrough Growth Initiative investment in Post-IPO Equity - Cardiff Oncology
Acorn Bioventures
Acorn Bioventures investment in Post-IPO Equity - Cardiff Oncology
CAM Capital
CAM Capital investment in Post-IPO Equity - Cardiff Oncology
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Cardiff Oncology
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Cardiff Oncology
Key Employee Changes
Official Site Inspections
http://www.cardiffoncology.com Semrush global rank: 4.11 M Semrush visits lastest month: 2.94 K
- Host name: 172.66.153.74
- IP address: 172.66.153.74
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Cardiff Oncology"
About - Cardiff Oncology
About Leadership Press releases Media Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel …See details»
Cardiff Oncology (CRDF) Company Profile & Description
Jun 27, 2025 Company profile for Cardiff Oncology, Inc. (CRDF) stock, with a description, list of executives, contact details and other key facts.See details»
Cardiff Oncology Company Profile - Office Locations ... - Craft
Oct 29, 2024 Cardiff Oncology has 1 employees at their 1 location and $683 k in annual revenue in FY 2024. See insights on Cardiff Oncology including office locations, competitors, revenue, …See details»
Press Releases - Cardiff Oncology, Inc.
Apr 15, 2025 The Investor Relations website contains information about Cardiff Oncology, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Cardiff Oncology - LinkedIn
Cardiff Oncology Biotechnology Research San Diego, California 5,264 followers Cardiff Oncology is a clinical-stage company with the mission of developing new treatment options for cancer …See details»
Cardiff Oncology Company Profile: , Investments, Contact …
Cardiff Oncology is a clinical-stage biotechnology company, headquartered in San Diego, CA, leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies …See details»
Management Team - Cardiff Oncology
By combining our collective oncology drug development and biomarker technology expertise with decades of experience, we are turning the tide on cancer.See details»
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical …
Jun 17, 2025 For more information, please visit https://www.cardiffoncology.com. Forward-Looking Statements Certain statements in this press release are forward-looking within the …See details»
Cardiff Oncology Inc. - Cruelty Free Investing
Cardiff Oncology Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatment for cancer patients. Its drug candidate includes onvansertib , which is a …See details»
Board of Directors - Cardiff Oncology
We are benefiting from the expertise of veteran pharmaceutical and biotech executives to align our current and future growth and success strategy.See details»
Contact Us - Cardiff Oncology
11055 Flintkote Ave, San Diego, CA 92121 858-952-7570 [email protected] Investor Relations: [email protected] Business Development: [email protected]See details»
Board of Directors - Cardiff Oncology, Inc.
Prior to her role at Elan, Dr. Tannenbaum spent three years leading the global commercial operations organization at Novartis Pharma AG, and nine and sixteen years at Bristol Myers …See details»
Media - Cardiff Oncology
Media Leadership Press releases Media Access Cardiff Oncology’s news highlights and learn more about our lead asset, onvansertib, and its role in advancing cancer treatment strategies. …See details»
SEC Filing - Cardiff Oncology, Inc.
The organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As the beneficial owner, you have the right to instruct this …See details»
Cardiff Oncology - Cardiff Oncology
Cardiff Oncology is a clinical-stage company with the singular mission of developing new oncology therapeutic options for cancer patients.See details»
Cardiff Oncology Announces Positive Data from Investigator …
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies …See details»
Mark Erlander, Ph.D. - Cardiff Oncology | LinkedIn
Dr. Erlander has a track record of over 20 years directing drug discovery efforts and… · Experience: Cardiff Oncology · Education: University of California, Los Angeles · Location: …See details»
Cardiff Oncology Appoints Roger Sidhu, MD as Chief Medical
Jun 17, 2025 Cardiff Oncology appoints Roger Sidhu as CMO; conference call on July 29 to discuss clinical data for onvansertib in mCRC.See details»
Cardiff Oncology Announces Positive Initial Data from First-line …
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies …See details»
Cardiff Oncology to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies …See details»